What is Hematogenix Laboratory Services?
Hematogenix Laboratory Services operates as a specialized Contract Research Organization (CRO) with a global footprint, dedicated exclusively to the advancement of cancer research and diagnostics. The firm distinguishes itself through a multidisciplinary team of board-certified clinical, anatomic, and hematopathologists. By maintaining CAP and CLIA certified, GCP-compliant laboratories, the company provides essential biomarker development and testing services that are fundamental to navigating the complexities of human subject clinical trials. Their market position is defined by a dual-focus approach: serving the pharmaceutical industry as a high-end research partner while simultaneously acting as a clinical and anatomical testing provider for the broader oncology community.
How much funding has Hematogenix Laboratory Services raised?
Hematogenix Laboratory Services has raised a total of $2.7M across 2 funding rounds:
Debt
$1M
Debt
$1.7M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.7M led by PPP
Key Investors in Hematogenix Laboratory Services
PPP
Public-Private Partnership
What's next for Hematogenix Laboratory Services?
With the recent infusion of capital, Hematogenix is well-positioned to accelerate its strategic initiatives in biomarker innovation and global laboratory expansion. The company is expected to further integrate advanced diagnostic technologies into its service portfolio, enhancing its capacity to support late-stage clinical trials and personalized medicine initiatives. As the firm continues to scale, the focus will likely remain on maintaining its high standards of regulatory compliance while expanding its reach into emerging oncology markets. This strategic growth trajectory suggests a continued commitment to bridging the gap between laboratory discovery and patient-centric clinical outcomes, ensuring that Hematogenix remains at the forefront of the oncology research sector.
See full Hematogenix Laboratory Services company page
